Sai Life Sciences Stock Screener | Share Price & Fundamental Analysis
SAILIFE
Pharmaceuticals
Screen Sai Life Sciences share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹976.10
▲
20.85 (2.18%)
Share Price BSE
₹975.10
▲
20.45 (2.14%)
Market Cap
₹20,531.50 Cr.
P/E Ratio (TTM)
71.91
P/B Ratio
9.07
EPS (TTM)
₹8.83
Dividend Yield
-
Debt to Equity
0.41
52W High
₹976.10
52W Low
₹640.25
Operating Margin
27.00%
Profit Margin
15.19%
Revenue (TTM)
₹553.00
EBITDA
₹161.00
Net Income
₹84.00
Total Assets
₹3,160.00
Total Equity
₹2,128.00
Sai Life Sciences Share Price History - Stock Screener Chart
Screen SAILIFE historical share price movements with interactive charts. Analyze price trends and patterns.
Sai Life Sciences Company Profile - Fundamental Screener
Screen Sai Life Sciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SAILIFE shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE570L01029
Sai Life Sciences Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen SAILIFE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total Assets | 3,160 | 2,275 | 2,187 | 2,157 | 1,817 | 1,410 |
| Current Assets | 1,505 | 945 | 964 | 944 | 804 | 613 |
| Fixed Assets | 1,488 | 1,180 | 1,037 | 751 | 753 | 641 |
| Liabilities | ||||||
| Total Liabilities | 3,160 | 2,275 | 2,187 | 2,157 | 1,817 | 1,410 |
| Current Liabilities | 299 | 560 | 540 | 565 | 356 | 149 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||
| Total Equity | 2,128 | 975 | 888 | 879 | 863 | 794 |
| Share Capital | 21 | 18 | 18 | 18 | 18 | 16 |
| Reserves & Surplus | 2,108 | 957 | 870 | 861 | 845 | 777 |
Screen SAILIFE income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Revenue | 553 | 506 | 589 | 449 | 406 | 288 | 443 | 395 |
| Expenses | 392 | 376 | 422 | 320 | 293 | 254 | 315 | 287 |
| EBITDA | 161 | 131 | 167 | 129 | 112 | 34 | 128 | 108 |
| Operating Profit % | 27.00% | 24.00% | 27.00% | 27.00% | 26.00% | 9.00% | 28.00% | 25.00% |
| Depreciation | 40 | 38 | 38 | 34 | 36 | 31 | 31 | 31 |
| Interest | 9 | 12 | 11 | 23 | 21 | 21 | 21 | 23 |
| Profit Before Tax | 112 | 81 | 119 | 72 | 55 | -18 | 76 | 53 |
| Tax | 28 | 20 | 31 | 18 | 14 | -5 | 20 | 13 |
| Net Profit | 84 | 61 | 88 | 54 | 42 | -14 | 56 | 40 |
| EPS | 4.01 | 2.90 | 4.24 | 2.89 | 2.22 | -0.74 | 31.00 | 2.19 |
Sai Life Sciences Cash Flow Screener - Liquidity Fundamentals
Screen SAILIFE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|
| Operating Activities | 314 | 263 | 219 | 105 | -36 | 116 | 129 |
| Investing Activities | -536 | -191 | -99 | -102 | -260 | -262 | -158 |
| Financing Activities | 301 | -95 | -201 | 72 | 296 | -4 | 268 |
| Net Cash Flow | 79 | -24 | -80 | 75 | -1 | -150 | 239 |
Screen SAILIFE shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jul |
|---|---|---|---|---|---|---|
| Promoter Holding | 34.93% | 35.15% | 35.17% | 35.24% | 35.24% | 39.64% |
| FII Holding | 22.49% | 14.58% | 12.36% | 11.72% | 7.64% | 0.00% |
| DII Holding | 29.94% | 21.64% | 13.26% | 11.95% | 5.61% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 7.90% | 6.56% | 7.69% | 8.88% | 18.68% | 0.00% |
| Other Holding | 4.74% | 22.07% | 31.52% | 32.22% | 32.84% | 60.36% |
| Shareholder Count | 119,704 | 126,380 | 140,677 | 82 | 572,970 | 70 |
Sai Life Sciences Dividend Screener - Share Yield Analysis
Screen SAILIFE dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Sai Life Sciences Index Membership - Market Screener Classification
Screen SAILIFE by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Sai Life Sciences Market Events Screener - Corporate Actions
Screen SAILIFE market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 8.86% | ||
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | 3.40% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -2.74% |
| 2025-05-13 | 2025-05-13 | Quarterly Result Announcement | NA | -0.61% |
| 2025-02-06 | 2025-02-06 | Quarterly Result Announcement | NA | -0.14% |
Sai Life Sciences Competitors Screener - Peer Comparison
Screen SAILIFE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 422,331 | 40.28 | 54,729 | 9.71% | 10,980 | 53.13 |
| Divis Laboratories | 176,338 | 70.98 | 9,712 | 18.67% | 2,191 | 63.15 |
| Torrent Pharmaceuticals | 133,239 | 62.26 | 11,539 | 6.99% | 1,911 | 71.28 |
| Cipla | 123,654 | 22.75 | 28,410 | 7.12% | 5,291 | 57.84 |
| Dr Reddys Laboratories | 104,846 | 18.27 | 33,741 | 16.73% | 5,725 | 46.16 |
| Lupin | 98,198 | 22.61 | 22,910 | 13.74% | 3,306 | 63.46 |
| Zydus Life Science | 93,685 | 18.63 | 23,511 | 18.55% | 4,615 | 54.52 |
| Mankind Pharma | 92,501 | 52.17 | 12,744 | 20.90% | 2,007 | 56.13 |
| Aurobindo Pharma | 71,514 | 20.91 | 32,346 | 9.43% | 3,484 | 60.21 |
| Alkem Laboratories | 67,620 | 28.04 | 13,458 | 3.70% | 2,216 | 55.49 |
Sai Life Sciences Company Announcements - News Screener
Screen SAILIFE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-01 | Receipt Of An Order Dated 30Th December 2025 Passed By The Additional Commissioner Ranga Reddy GST Commissionerate Hyderabad U/S 74 Of The Central Goods And Services Tax Act 2017 | View |
| 2025-12-30 | Closure of Trading Window | View |
| 2025-12-19 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-12-19 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-11 | An Order Dated 09Th December 2025 Was Passed By The Deputy Commissioner Of Commercial Taxes (Audit) Bidar DGSTO Kalaburagi U/S 73(9) Of The Integrated Goods And Services Tax Act 2017. | View |
| 2025-12-08 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-12-08 | An Order Dated 06Th December 2025 Has Been Passed By The Joint Commissioner Of Commercial Taxes (Appeals) Kalaburagi Under Section 107(11) Of The Karnataka Goods And Services Tax Act 2017. | View |
| 2025-11-25 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-23 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-11-20 | Intimation For Order Dated 19Th November 2025 Issued By The Joint Commissioner Of Commercial Taxes (Appeals) Kalaburagi U/S 107 (11) Of The Karnataka Goods And Services Tax Act 2017 And The Central Goods And Services Tax Act 2017. | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-13 | Intimation Of Order Dated 12Th November 2025 Passed By The Assistant Commissioner Central Tax Division-II (Pimpri) Pune-I Commissionerate U/S 74 Of The CGST Act 2017. | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-06 | Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended On 30 September 2025 | View |